{
    "nctId": "NCT02580799",
    "briefTitle": "Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples",
    "officialTitle": "Immunohistochemical HER2 Status Evaluation In Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nSamples that fulfill all of the criteria will be evaluated for the study.\n\n* Samples of women aged greater than or equal to (\\>/=) 18 and less than (\\<) 75 years\n* Tumor samples already diagnosed based on the IHC score of 0 to +3\n* Samples of primary lesions excluding lymph nodes\n* 10 percent (%) neutral buffered formalin-fixed and paraffin embedded tissue samples\n\nExclusion Criteria:\n\nSamples that fulfill any of the criteria below will not be included in the study.\n\n* Non-invasive ductal carcinoma (NOS) samples\n* Tru-cut biopsies\n* Non-breast cancer pathological samples",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}